{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:11:55Z","timestamp":1788455515302,"version":"build-2803163510"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Persistent infection with high\u2212risk human papillomavirus (HPV) is the primary cause of cervical cancer; however, the prognostic role of HPV viral load and its association with the tumor immune microenvironment remain incompletely understood. This study aimed to systematically evaluate the association between HPV viral load and disease progression, prognosis, and tumor immune microenvironment in patients with cervical cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort of 278 patients with cervical neoplasia was analyzed. HPV viral load was quantified and log\n                      <jats:sub>10<\/jats:sub>\n                      -transformed. Patients were categorized into low- and high-viral load groups using segmented regression. Clinical characteristics, recurrence, metastasis, and survival were compared. Immune parameters (CD3\n                      <jats:sup>+<\/jats:sup>\n                      , CD4\n                      <jats:sup>+<\/jats:sup>\n                      , CD8\n                      <jats:sup>+<\/jats:sup>\n                      , FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      T cells, programmed death-ligand 1 [PD-L1] expression), serum tumor markers (squamous cell carcinoma antigen [SCC], cancer antigen 125 [CA125], CA199, carcinoembryonic antigen [CEA]), Ki67, p16, and sex hormone levels were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      High HPV viral load (log\n                      <jats:sub>10<\/jats:sub>\n                      \u22655.6) was significantly associated with advanced disease stage (p &amp;lt; 0.001), lymph node metastasis (28.3% vs. 13.5%, p = 0.002), and higher recurrence rates (27.4% vs. 13.0%, p = 0.002). Five-year overall survival (OS) (68.5% vs. 87.3%) and recurrence-free survival (RFS) (59.3% vs. 82.1%) showed a trend toward worse outcomes in the high viral load group, but the differences were not statistically significant (log-rank p = 0.38 and p = 0.068, respectively). Multivariable Cox analysis confirmed high viral load as an independent predictor of recurrence (hazard ratio [HR] 2.18, 95% confidence interval [CI] 1.32\u20133.61, p = 0.002). High viral load correlated with reduced tumor-infiltrating lymphocytes (TILs) (CD3\n                      <jats:sup>+<\/jats:sup>\n                      : 12.1% vs. 18.3%, p = 0.001), lower PD-L1 positivity (36.4% vs. 63.2%, p = 0.045), and higher Ki67 expression (58.3% vs. 42.5%, p = 0.003). Combining viral load with serum SCC improved prediction of high-grade lesions (area under the curve [AUC] 0.78 vs. 0.73, p = 0.02) and recurrence (C-index 0.71 vs. 0.65). Machine learning models ranked viral load as the top predictor. Post-treatment viral load decline was significantly associated with lower recurrence risk (odds ratio [OR] 4.12 for slow decline, p = 0.02). In premenopausal women, estradiol levels correlated positively with viral load (\u03c1 = 0.31, p = 0.003) and disease severity. A correlation network revealed a cluster linking high viral load, low immune infiltration, and high proliferation. The prognostic effect of viral load was consistent across HPV types and was more pronounced in advanced-stage patients (interaction p = 0.09).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High HPV viral load is an independent predictor of poor prognosis in cervical cancer, associated with an immunosuppressive tumor microenvironment and enhanced proliferative activity. Incorporating viral load into routine assessment may improve risk stratification and guide personalized treatment strategies, particularly for patients with high viral load who may benefit from immune-enhancing therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1840435","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:10:16Z","timestamp":1782108616000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["HPV viral load predicts immune exhaustion and prognosis in cervical neoplasia"],"prefix":"10.3389","volume":"17","author":[{"given":"Yibo","family":"Guo","sequence":"first","affiliation":[{"name":"Clinical Laboratory, The First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanrui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"He","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, The First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, The First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Lu","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, The First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, The First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4819","article-title":"Human papillomavirus-associated oropharyngeal cancer: review of current evidence and management","volume":"26","author":"You","year":"2019","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3142","article-title":"Human papilloma virus, DNA methylation and microRNA expression in cervical cancer (review)","volume":"31","author":"Jim\u00e9nez-Wences","year":"2014","journal-title":"Oncol Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.71843","article-title":"Cervical cancer, HPV, and HPV vaccine knowledge and willingness to be vaccinated among adolescent girls in Dhaka, Bangladesh: a cross-sectional study","volume":"9","author":"Ripon","year":"2026","journal-title":"Health Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7196\/samj.6936","article-title":"Paradigm shift needed for cervical cancer: HPV infection is the real epidemic","volume":"103","author":"Richter","year":"2013","journal-title":"South Afr Med J = Suid-Afrikaanse Tydskrif Vir Geneeskunde"},{"key":"B5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12032-020-01363-z","article-title":"HR-HPV viral load quality detection provide more accurate prediction for residual lesions after treatment: a prospective cohort study in patients with high-grade squamous lesions or worse","volume":"37","author":"Chen","year":"2020","journal-title":"Med Oncol (Northwood London England)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/life15020153","article-title":"Evaluating HPV viral load and multiple infections for enhanced cervical cancer risk-based assessment","volume":"15","author":"Varesano","year":"2025","journal-title":"Life (Basel Switzerland)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2025.2510668","article-title":"High HPV viral load predicts worse prognosis in patients with cervical cancer treated with radiochemotherapy","volume":"101","author":"Wang","year":"2025","journal-title":"Int J Radiat Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29741","article-title":"Increased human papillomavirus viral load is correlated to higher severity of cervical disease and poorer clinical outcome: a systematic review","volume":"96","author":"Fobian","year":"2024","journal-title":"J Med Virol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13224-013-0499-7","article-title":"HPV viral load determination during pregnancy as a possible cervical cancer risk","volume":"25","author":"Bandyopadhyay","year":"2006","journal-title":"J Exp Clin Cancer Res Cr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2008.19.2.113","article-title":"Does pretreatment HPV viral load correlate with prognosis in patients with early stage cervical carcinoma","volume":"19","author":"Kim","year":"2008","journal-title":"J Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0119","article-title":"Expansion of candidate HPV-specific T cells in the tumor microenvironment during chemoradiotherapy is prognostic in HPV16(+) cancers","volume":"10","author":"Colbert","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.6026\/97320630019556","article-title":"Role of T cells in cervical cancer","volume":"19","author":"Alshami","year":"2023","journal-title":"Bioinformation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ygyno.2005.11.039","article-title":"Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and Malignant lesions of the uterine cervix","volume":"102","author":"Monnier-Benoit","year":"2006","journal-title":"Gynecol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-018-0674-4","article-title":"PD-1\/PD-L1 blockade in cervical cancer: current studies and perspectives","volume":"13","author":"Wang","year":"2019","journal-title":"Front Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41392-025-02294-9","article-title":"Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3\/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study","volume":"10","author":"Sheng","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091629","article-title":"Serum proteomic signatures in cervical cancer: current status and future directions","volume":"16","author":"Weaver","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.biopha.2003.11.003","article-title":"Serum tumor markers in the management of ovarian, endometrial and cervical cancer","volume":"58","author":"Gadducci","year":"2004","journal-title":"Biomedicine Pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1776403","article-title":"Combined oral contraceptive use and the risk of cervical cancer: literature review","volume":"45","author":"Bovo","year":"2023","journal-title":"Rev Bras Ginecologia E Obstetricia Rev Da Federacao Bras Das Sociedades Ginecologia E Obstetricia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2021.198602","article-title":"ERa-36 instead of ERa mediates the stimulatory effects of estrogen on the expression of viral oncogenes HPV E6\/E7 and the Malignant phenotypes in cervical cancer cells","volume":"306","author":"Zhang","year":"2021","journal-title":"Virus Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101924","article-title":"High human papillomavirus viral load and local immune dysregulation are associated with poor clinical outcomes in patients with cervical cancer","volume":"35","author":"Mei","year":"2025","journal-title":"Int J Gynecological Cancer Off J Int Gynecological Cancer Soc"},{"key":"B21","doi-asserted-by":"publisher","first-page":"15075","DOI":"10.1038\/s41598-023-42022-3","article-title":"Increased expression of HPV-E7 oncoprotein correlates with a reduced level of pRb proteins via high viral load in cervical cancer","volume":"13","author":"Mir","year":"2023","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.08.025","article-title":"Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape","volume":"131","author":"Conesa-Zamora","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.5.3186","article-title":"TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16","volume":"178","author":"Hasan","year":"2007","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.221","article-title":"Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer","volume":"30","author":"Enwere","year":"2017","journal-title":"Modern Pathol Off J United States Can Acad Pathology Inc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1487296","article-title":"From cold to hot: mechanisms of hyperthermia in modulating tumor immunology for enhanced immunotherapy","volume":"16","author":"Abreu","year":"2025","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01018-w","article-title":"Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer","volume":"6","author":"Huang","year":"2025","journal-title":"Nat Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2024.05.016","article-title":"Role of squamous cell carcinoma antigen (SCC-Ag) in the management of carcinoma cervix in an Indian population: a pilot study","volume":"81","author":"Singh","year":"2025","journal-title":"Med Journal Armed Forces India"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2051","article-title":"Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer","volume":"68","author":"Chung","year":"2008","journal-title":"Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1840435\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:10:17Z","timestamp":1782108617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1840435\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1840435"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1840435","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1840435"}}